Schrodinger Inc

Schrödinger is a computational platform company transforming molecular discovery for drug development and materials design. Its software platform, built on more than 30 years of R&D investment, integrates physics-based simulation with AI and machine learning to enable the discovery of novel, highly optimized molecules. The platform is licensed by biotechnology, pharmaceutical, and industrial companies, as well as academic institutions globally. In addition to its software business, Schrödinger leverages the platform to advance a portfolio of collaborative and proprietary drug discovery programs spanning over twenty-five first-in-class, best-in-class, and first-in-modality programs across all stages of development, including more than ten clinical-stage programs. The company generates revenue from two segments: software products and services, and drug discovery collaborations. Schrödinger has co-founded multiple therapeutics companies including Structure Therapeutics, Ajax Therapeutics, and Nimbus, and holds equity stakes and royalty eligibility in various programs. Since 2020, the company has generated over $650 million in cash from drug discovery initiatives and is eligible for up to nearly $5 billion in potential future milestones. Updated May 18, 2026